PolyNovo Limited announced resignation of Dr. David McQuillan asNon-executive Director and his appointment as Chief Technical and Scientific Officer of the Company. David is an experienced MedTech executive with extensive experience across start-up, early-stage commercial, and mid-cap medical technology companies. Dr. McQuillan spent 20 years managing research and development for leading companies in regenerative medicine and wound healing, including LifeCell (acquired by Allergan), Kinetic Concepts (acquired by 3M), and Tela bio.

Dr. McQuillan has launched market leading products in regenerative medicine for dermal replacement, hernia repair, abdominal wall reconstruction, wound healing, breast reconstruction and orthopedic soft tissue repair. David spent over 15 years in academic research focused on tissue engineering and regenerative medicine, including being involved in foundational work at the National Institute of Health (NIH, Bethesda, MD), the University of Melbourne (Orthopedic Research, Royal Children's Hospital), and Texas A&M University (Institute of Biosciences & Technology, Houston, TX). David holds a BSc (Hons) and PhD (Biochemistry) from Monash University.